Decoded: Why India's $130 billion pharma ambition faces a hurdle as investigation backlogs delay drug batch releases
New Delhi, Nov. 4 -- India's pharmaceutical industry is working towards a $130 billion ambition by 2030. However, as manufacturers look to expand production and strengthen their position in global markets, operational challenges within factories could affect how efficiently they manufacture and release drug batches.
A study by management consulting firm Vector Consulting Group has highlighted one such challenge: the growing burden of manufacturing incidents and delays in closing investigations. These backlogs are affecting batch-release timelines and consuming a significant share of senior management's time, raising questions about how efficiently pharmaceutical plants can scale their operations.
The white paper, The Compliance Spiral i...
Click here to read full article from source
इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया
हमे संपर्क करें.